116 related articles for article (PubMed ID: 37769336)
21. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
[TBL] [Abstract][Full Text] [Related]
22. Short-term and long-term survival of interval breast cancers taking into account prognostic features.
Delacour-Billon S; Mathieu-Wacquant AL; Campone M; Auffret N; Amossé S; Allioux C; Cowppli-Bony A; Molinié F
Cancer Causes Control; 2017 Jan; 28(1):69-76. PubMed ID: 27995351
[TBL] [Abstract][Full Text] [Related]
23. Tumour characteristics and survival in patients with invasive interval breast cancer classified according to mammographic findings at the latest screening: a comparison of true interval and missed interval cancers.
Vitak B; Olsen KE; Månson JC; Arnesson LG; Stål O
Eur Radiol; 1999; 9(3):460-9. PubMed ID: 10087117
[TBL] [Abstract][Full Text] [Related]
24. Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ.
Dania V; Liu Y; Ademuyiwa F; Weber JD; Colditz GA
Breast Cancer Res; 2019 Nov; 21(1):120. PubMed ID: 31727116
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy.
Donaldson AR; McCarthy C; Goraya S; Pederson HJ; Sturgis CD; Grobmyer SR; Calhoun BC
Cancer; 2018 Feb; 124(3):459-465. PubMed ID: 29023647
[TBL] [Abstract][Full Text] [Related]
26. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
Di Carlo V; Stiller CA; Eisemann N; Bordoni A; Matz M; Curado MP; Daubisse-Marliac L; Valkov M; Bulliard JL; Morrison D; Johnson C; Girardi F; Marcos-Gragera R; Šekerija M; Larønningen S; Sirri E; Coleman MP; Allemani C;
Br J Dermatol; 2022 Sep; 187(3):364-380. PubMed ID: 35347700
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis.
Wong SM; Stout NK; Punglia RS; Prakash I; Sagara Y; Golshan M
Cancer; 2017 Jul; 123(14):2609-2617. PubMed ID: 28221673
[TBL] [Abstract][Full Text] [Related]
28. Trends in net survival lung cancer in six European Latin countries: results from the SUDCAN population-based study.
Bordoni A; Uhry Z; Antunes L;
Eur J Cancer Prev; 2017 Jan; 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study():S70-S76. PubMed ID: 28005608
[TBL] [Abstract][Full Text] [Related]
29. Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study.
Mukama T; Fallah M; Brenner H; Xu X; Sundquist K; Sundquist J; Kharazmi E
BMC Med; 2020 Nov; 18(1):295. PubMed ID: 33148280
[TBL] [Abstract][Full Text] [Related]
30. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade.
Baker K; Lachapelle J; Zlobec I; Bismar TA; Terracciano L; Foulkes WD
Histopathology; 2011 Jun; 58(7):1107-16. PubMed ID: 21707712
[TBL] [Abstract][Full Text] [Related]
32. Comparing net survival estimators of cancer patients.
Seppä K; Hakulinen T; Läärä E; Pitkäniemi J
Stat Med; 2016 May; 35(11):1866-79. PubMed ID: 26707551
[TBL] [Abstract][Full Text] [Related]
33. Is carcinoma in situ a precursor lesion of invasive breast cancer?
To T; Wall C; Baines CJ; Miller AB
Int J Cancer; 2014 Oct; 135(7):1646-52. PubMed ID: 24615647
[TBL] [Abstract][Full Text] [Related]
34. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
[TBL] [Abstract][Full Text] [Related]
35. Cause-specific mortality in women with breast cancer in situ.
He W; Sofie Lindström L; Hall P; Czene K
Int J Cancer; 2017 Jun; 140(11):2414-2421. PubMed ID: 27594272
[TBL] [Abstract][Full Text] [Related]
36. Does access to care play a role in liver cancer survival? The ten-year (2006-2015) experience from a population-based cancer registry in Southern Italy.
Mazzucco W; Vitale F; Mazzola S; Amodio R; Zarcone M; Alba D; Marotta C; Cusimano R; Allemani C
BMC Cancer; 2021 Mar; 21(1):307. PubMed ID: 33761907
[TBL] [Abstract][Full Text] [Related]
37. Breast screening and breast cancer survival in Aboriginal and Torres Strait Islander women of Australia.
Roder D; Webster F; Zorbas H; Sinclair S
Asian Pac J Cancer Prev; 2012; 13(1):147-55. PubMed ID: 22502658
[TBL] [Abstract][Full Text] [Related]
38. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
[TBL] [Abstract][Full Text] [Related]
39. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
40. Proliferative epithelial changes in tumour adjacent tissue in Sri Lankan women with breast carcinoma: do morphological changes support molecular models of breast carcinogenesis?
Jinadasa IM; Wijesinghe HD; Jayawickrama MMA; Lokuhetty MDS
Diagn Pathol; 2022 Dec; 17(1):97. PubMed ID: 36581929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
